Simultaneously Targeting the NS3 Protease And Helicase Activities For More Effective Hepatitis C Virus Therapy

View/ Open
Issue Date
2015-08-21Author
Ndjomou, Jean
Corby, M. Josie
Sweeney, Noreena L.
Hanson, Alicia M.
Aydin, Cihan
Ali, Akbar
Schiffer, Celia A.
Li, Kelin
Frankowski, Kevin J.
Schoenen, Frank J.
Frick, David N.
Publisher
ACS
Type
Article
Article Version
Scholarly/refereed, author accepted manuscript
Rights
Copyright © 2015 American Chemical Society
Metadata
Show full item recordAbstract
This study examines the specificity and mechanism of action of a recently reported hepatitis C virus (HCV) non-structural protein 3 (NS3) helicase-protease inhibitor (HPI), and the interaction of HPI with the NS3 protease inhibitors telaprevir, boceprevir, danoprevir, and grazoprevir. HPI most effectively reduced cellular levels of subgenomic genotype 4a replicons, followed by genotypes 3a and 1b replicons. HPI had no effect on HCV genotype 2a or dengue virus replicon levels. Resistance evolved more slowly to HPI than telaprevir, and HPI inhibited telaprevir-resistant replicons. Molecular modeling and analysis of the ability of HPI to inhibit peptide hydrolysis catalyzed by a variety of wildtype and mutant NS3 proteins suggested that HPI forms a bridge between the NS3 RNA-binding cleft and an allosteric site previously shown to bind other protease inhibitors. In most combinations, the antiviral effect of HPI was additive with telaprevir, boceprevir, minor synergy was observed with danoprevir and modest synergy was observed with grazoprevir.
Collections
Citation
Ndjomou, J., Corby, M. J., Sweeney, N. L., Hanson, A. M., Aydin, C., Ali, A., … Frick, D. N. (2015). Simultaneously Targeting the NS3 Protease And Helicase Activities For More Effective Hepatitis C Virus Therapy. ACS Chemical Biology, 10(8), 1887–1896. http://doi.org/10.1021/acschembio.5b00101
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.